AEON Biopharma (AEON) Stock Statistics & Valuation Metrics

AEON Biopharma has a market cap or net worth of $26.57M. The enterprise value is $45.04M.

AEON Biopharma has 25,303,059 shares outstanding. The number of shares has decreased by -2.65% in one year.

AEON Biopharma’s return on equity (ROE) is 0.71 and return on invested capital (ROIC) is 1557.79%.

The current PE Ratio of AEON Biopharma is ―. AEON Biopharma’s PEG ratio is 0.00265.

In the last 12 months, AEON Biopharma had revenue of 0.00 and earned -39.22M in profits. Earnings per share was -3.95.

In the last 12 months, operating cash flow was -17.31M and capital expenditures -4.00K, giving a free cash flow of -17.31M billion.

AEON Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

AEON Biopharma upcoming earnings date is May 20, 2026, Before Open (Confirmed).

AEON Biopharma as a current ratio of 0.49, with Debt / Equity ratio of -64.96%

In the past 12 months, AEON Biopharma has paid 0.00 in taxes.

AEON Biopharma EV to EBITDA ratio is -2.59, with an EV/FCF ratio of -2.52.

AEON Biopharma has $3.01M in cash and marketable securities with $35.74M in debt, giving a net cash position of -$32.74M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for AEON Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―